Truist Securities Reiterates Rating on Insulet Corporation $PODD
Key Points
- Truist Securities now rates Insulet Corporation ($PODD) "buy" with a $219 target.
- Truist Securities's $219 price target implies 52.59% upside from Insulet Corporation's ($PODD) current $143.52 share price.
- The Street's average $PODD price target is $171.91.
- $PODD last traded around $143.52.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities reiterated its rating on Insulet Corporation ($PODD) to a "buy" rating in a recent research note and set a price target of $219, a 52.59% upside from the current price.
Insulet Corporation Stock Down 1.1%
Shares of Insulet Corporation ($PODD) traded around $143.52 on Saturday, down 1.1% for the day.
Insulet Corporation Earnings
Analysts Set New Price Targets
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Get Insulet Corporation alerts
New 13F filings, insider trades, and analyst moves on $PODD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.